Do the therapeutic effects of psilocybin involve actions in the gut?
Trends in Pharmacological Sciences February 1, 2024 DOI: 10.1016/j.tips.2023.12.007 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Topics | Neuroplasticity Psilocybin Serotonin |
| Keywords | Gut–brain axis Mental health Vagus nerve Psychedelics hallucinogens Entheogens Gut-brain connection Neuroscience neuroplast |
| Citations | 22 |
| Key points | Argues that peripheral actions of psilocybin in the gastrointestinal tract may contribute to rapid and long-term therapeutic effects in mental health conditions. |
Abstract
The psychedelic compound psilocybin has recently emerged as a therapeutic intervention for various mental health conditions. Psilocybin is a potent agonist of serotonin (5-HT) receptors (5-HTRs), which are expressed in the brain and throughout peripheral tissues, with particularly high expression in the gastrointestinal (GI) tract. However, no studies have investigated the possibility that peripheral actions of psilocybin may contribute to improvements in mental health outcomes. This is despite strong evidence for disturbed gut-brain signalling in conditions in which psilocybin is being tested clinically. In this Opinion, we highlight the likely actions of psychedelics in the gut and provide initial support for the premise that peripheral actions may be involved in rapid and long-term therapeutic effects. A greater understanding of all sites and modes of action will guide more targeted approaches to drug development.